AstraZeneca shares dropped as a lot as 7% after a report that the U.Ok.’s largest drugmaker was in talks with U.S. peer Bristol Myers Squibb over a megadeal that, if accomplished, may worth the businesses at roughly $400 billion.
AstraZeneca declined to remark. Bristol Myers Squibb did not instantly reply to a request to remark outdoors of regular working hours.
The businesses have mentioned a possible merger over a number of months, the Monetary Instances reported on Sunday. It will be one of many largest offers ever.
AstraZeneca’s London-listed shares had been final seen buying and selling 6.5% decrease in early morning buying and selling, weighing on the U.Ok.’s blue-chip index FTSE 100, which was largely flat.
That is breaking information. Please refresh for updates.
